Outlook therapeutics® receives european commission marketing authorization for lytenava™ (bevacizumab gamma) for the treatment of wet amd

Iselin, n.j., may 28, 2024 (globe newswire) -- outlook therapeutics, inc. (nasdaq: otlk), a biopharmaceutical company focused on the commercialization and development of ons-5010/lytenava™ (bevacizumab-vikg; bevacizumab gamma), for the treatment of retina diseases, today announced that the european commission has granted marketing authorization for lytenava™ (bevacizumab gamma), an ophthalmic formulation of bevacizumab for the treatment of wet amd in the eu. lytenava™ (bevacizumab gamma) is the first and only authorized ophthalmic formulation of bevacizumab for use in treating wet amd in the eu.
AMD Ratings Summary
Quant
AMD Quant Ranking
Sector
Industry
Quant Rating
Quant Score